Inicio>>Signaling Pathways>> Others>>Eslicarbazepine

Eslicarbazepine

Catalog No.GC36008

La eslicarbazepina es un anticonvulsivo oral indicado para el tratamiento adyuvante de las convulsiones parciales.

Products are for research use only. Not for human use. We do not sell to patients.

Eslicarbazepine Chemical Structure

Cas No.: 104746-04-5

Tamaño Precio Disponibilidad Cantidad
5mg
56,00 $
Disponible
10mg
93,00 $
Disponible
25mg
176,00 $
Disponible
50mg
269,00 $
Disponible
100mg
417,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

Eslicarbazepine is an anti-epileptic drug, chemically related to carbamazepine but with a more favorable safety profile. Eslicarbazepine acetate is a prodrug for eslicarbazepine (S-licarbazepine), which is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel[1][2].

References:
[1]. Finelli E, et al. Patch testing in a case of eslicarbazepine and carbamazepine induced cutaneous reaction. Eur Ann Allergy Clin Immunol. 2018 Sep;50(5):229-231.
[2]. Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.

Reseñas

Review for Eslicarbazepine

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Eslicarbazepine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.